Phaclofen: Difference between revisions
CSV import |
No edit summary |
||
| Line 23: | Line 23: | ||
{{stub}} | {{stub}} | ||
<gallery> | <gallery> | ||
File:Phaclofen.svg|Phaclofen | File:Phaclofen.svg|Phaclofen | ||
</gallery> | </gallery> | ||
Latest revision as of 00:57, 17 March 2025
Phaclofen is a GABAB receptor antagonist drug that was first described in the literature in 1981. It is used in scientific research and has no known therapeutic use in humans.
History[edit]
Phaclofen was first described in the literature in 1981. It was developed as a research tool for studying the GABAB receptor, a type of G protein-coupled receptor that is found in the brain and spinal cord. The GABAB receptor is involved in a variety of physiological processes, including inhibition of neuronal activity and modulation of neurotransmitter release.
Pharmacology[edit]
Phaclofen acts as an antagonist at the GABAB receptor, meaning that it blocks the action of the neurotransmitter gamma-aminobutyric acid (GABA) at this receptor. This makes it a useful tool for studying the role of the GABAB receptor in various physiological processes.
Research Use[edit]
Phaclofen has been used in a variety of research studies to investigate the role of the GABAB receptor in the brain and spinal cord. For example, it has been used to study the role of this receptor in pain perception, memory formation, and the regulation of mood and anxiety.
See Also[edit]
References[edit]
<references />
